CUSIP No. 91381U200
|
SCHEDULE 13G
|
Page 4
of 9 Pages
|
|
|
|
|
|
1
|
NAME OF REPORTING PERSONS
Anand Parekh
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) o
|
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
0
|
6
|
SHARED VOTING POWER
1,419,000
|
7
|
SOLE DISPOSITIVE POWER
0
|
8
|
SHARED DISPOSITIVE POWER
1,419,000
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,419,000
|
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
o
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.99%*
|
12
|
TYPE OF REPORTING PERSON
IN
|
The reporting persons are the beneficial owners of 1,419,000
shares of Common Stock of the Issuer, which constitute approximately 9.99% of the Issuer’s outstanding Common Stock shares. The
percentage calculation assumes that there are currently 14,192,305 outstanding shares of Common Stock of the Issuer, based on the Issuer’s
Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on November 8, 2022.
CUSIP
No. 91381U200
|
SCHEDULE 13G
|
Page 5
of 9 Pages
|
Item 1. | | (a) Name of Issuer |
Unity Biotechnology, Inc.
Item 1. | | (b) Address of Issuer’s Principal
Executive Offices |
285 East Grand Ave.
South San Francisco, CA 94080
Item 2. | | (a) Names of Person Filing: |
(i) Alyeska Investment Group, L.P.
(ii) Alyeska Fund GP, LLC
(iii) Anand Parekh
Item 2. | | (b) Address of Principal Business Office: |
(i)
77 West Wacker Drive, 7th Floor
Chicago,
IL 60601
(ii)
77 West Wacker Drive, 7th Floor
Chicago,
IL 60601
(iii)
77 West Wacker Drive, 7th Floor
Chicago,
IL 60601
(i)
Alyeska Investment Group, L.P. - Delaware
(ii)
Alyeska Fund GP, LLC - Delaware
(iii)
Anand Parekh - United States of America
Item 2. | | (d) Title of Class of Securities |
Common Stock, par value $0.0001
91381U200
CUSIP No. 91381U200
|
SCHEDULE 13G
|
Page 6
of 9 Pages
|
|
Item 3. If
this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
|
(a) |
¨ |
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); |
|
|
(b) |
¨ |
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); |
|
|
(c) |
¨ |
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); |
|
|
(d) |
¨ |
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); |
|
|
(e) |
x |
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); |
|
|
(f) |
¨ |
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); |
|
|
(g) |
x |
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); |
|
|
(h) |
¨ |
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
|
|
(i) |
¨ |
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the
Investment Company Act of 1940 (15 U.S.C. 80a-3); |
|
|
(j) |
¨ |
A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); |
|
|
(k) |
¨ |
A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J),
please specify the type of institution: |
|
|
|
|
CUSIP
No. 91381U200
|
SCHEDULE 13G
|
Page
7 of 9 Pages
|
Item
4. Ownership
Provide
the following information regarding the aggregate number and percentage of the class of securities of the issuer identified
in Item 1.
(a)
Amount beneficially owned: Please refer to items 5-9 of the cover pages attached hereto
(b)
Percent of class: Please refer to item 11 of the cover pages attached hereto
(c)
Number of shares as to which the person has: Please refer to items 5-8 of the cover pages attached hereto
The reporting persons are the beneficial owners of 697,448
shares of Common Stock of the Issuer and hold warrants to purchase 1,286,000 shares of the Issuer’s Common Stock (the “Warrants”).
However, per their terms, the Warrants can only be exercised into such number of shares that would constitute 9.9% of the total number
of Common Stock of the Issuer outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this
Warrant by the Holder. Accordingly, as of December 31, 2022 the reporting persons may only exercise up to 721,512 shares of Common
Stock under the Warrant Agreement, and as such, is reporting beneficial ownership of only such number of shares. The percentage
calculation assumes that there are currently 14,192,305 outstanding shares of Common Stock of the Issuer, based on the Issuer’s
Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on November 8, 2022.
Item
5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check the following [ ].
Item
6. Ownership of More Than Five Percent on Behalf of Another Person
Not Applicable.
Item
7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent
Holding Company or Control Person
Not Applicable.
Item
8. Identification and Classification of Members of the Group
Not Applicable.
Item
9. Notice of Dissolution of Group
Not Applicable.
Item
10. Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired
and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of
changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with
or as a participant in any transaction having that purpose or effect.
CUSIP No. 91381U200
|
SCHEDULE 13G
|
Page
8 of 9 Pages
|
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 14, 2023
|
|
Alyeska Investment Group, L.P.
|
|
|
|
|
|
By: |
/s/
Jason Bragg |
|
|
Jason Bragg, Chief Financial Officer |
|
|
|
|
|
Alyeska Fund GP, LLC
|
|
|
|
|
|
By: |
/s/
Jason Bragg |
|
|
Jason Bragg, Chief Financial Officer |
|
Anand Parekh
By: Entity
and Description |
|
|
|
|
|
By: |
/s/
Anand Parekh |
|
|
Anand Parekh, Individually |
|
|
|
|
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned
and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned
without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible
for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained
therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to
the extent that he or it knows or has reason to believe that such information is inaccurate.